IP Library › Granted Patent US 10,006,026
Granted Patent B2
US 10,006,026 · App. 14/775,233 · Granted Jun 26, 2018

Recombinant polypeptide production

Inventors: Katie Streicher (Gaithersburg, MD); Jonathan Jacobs (Gaithersburg, MD); Robert W. Georgantas, III (Gaithersburg, MD); Lydia Greenlees (Gaithersburg, MD); Koustubh Ranade (Gaithersburg, MD); Michael Bowen (Gaithersburg, MD)
Assignee: MedImmune, LLC
C12N15/113C07K14/705C07K16/00C07K16/4208C12N9/00C12P21/02C07K2317/14C07K2317/21C07K2317/22C07K2317/24C07K2317/31C07K2317/40C07K2317/565C07K2317/622C12N2310/113C12N2330/50C12N2799/027C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,006,026
App. No.
14/775,233
Granted
Jun 26, 2018
Kind
B2
Abstract

Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.

Claims (28)

1. A method of producing a recombinant polypeptide in a mammalian cell culture, the method comprising:

(a) obtaining mammalian cells having reduced miRNA-let-7a activity;

(b) culturing the mammalian cells to produce the recombinant polypeptide; and

(c) recovering the protein

wherein the miRNA-let-7a activity is reduced by a microRNA inhibitor.

2. The method of claim 1 , wherein the microRNA inhibitor comprises an antisense oligonucleotide inhibitor of miRNA-let-7a.

3. The method of claim 2 , wherein the oligonucleotide inhibitor is chemically modified to improve nuclease resistance, to increase resistance to miRNA-directed cleavage by RISC and/or to increase binding affinity.

4. The method of claim 1 , wherein the mammalian cell culture comprises mammalian cells that are transfected with an expression vector encoding the antisense oligonucleotide inhibitor of miRNA-let-7a.

5. The method of claim 1 , wherein the mammalian cell culture comprises mammalian cells that are stably transfected with an antisense oligonucleotide inhibitor of miRNA-let-7a.

6. The method of claim 1 , wherein the mammalian cell culture comprises mammalian cells that are transiently transfected with an antisense oligonucleotide inhibitor of miRNA-let-7a.

7. The method of claim 1 , wherein the mammalian cell culture comprises mammalian cells selected from: Chinese hamster ovary (CHO) cells, mouse myeloma (NS0), human embryonic kidney (HEK 293), baby hamster kidney (BHK) cells, Vero cells, HeLa cells, Madin-Darby Canine Kidney (MDCK) cells, CV1 monkey kidney cells, 3T3 cells, myeloma cell lines, PC12, WI38 cells, COS-7 lines of monkey kidney fibroblasts, and C127.

8. The method of claim 1 , wherein the mammalian cells comprise Chinese hamster ovary cells.

9. A method of producing a recombinant polypeptide in a mammalian cell culture, the method comprising:

(a) obtaining mammalian cells having reduced miRNA-let-7a activity;

(b) culturing the mammalian cells to produce the recombinant polypeptide; and

(c) recovering the protein

wherein the mammalian cells having reduced miRNA-let-7a activity comprise miRNA-let-7a genetic knockouts.

10. The method of claim 1 , wherein the recombinant polypeptide is selected from the group consisting of an antibody or binding fragment thereof, a non-antibody protein, a fusion protein, a receptor, a ligand of a cell surface protein, a receptor, a secreted protein, and an enzyme.

11. The method of claim 10 , wherein the antibody or binding fragment thereof is selected from multispecific antibodies, fully human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, CDR-grafted antibodies, single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), Fab fragments, F(ab′) fragments, and anti-idiotypic (anti-Id) antibodies.

12. The method of claim 1 , wherein the cell culture has a specific productivity that is increased at least about 25% compared to a control cell culture that does not have reduced miRNA-let-7a activity.

13. The method of claim 1 , wherein the cell culture has a maximum productivity determined at peak viable cell density (VCD) that is increased at least about 25% when compared to a control cell culture that does not have reduced miRNA-let-7a activity.

14. The method of claim 1 , wherein the cell culture has an increased specific productivity when compared to a control mammalian cell culture that does not have reduced miRNA-let-7a activity.

15. The method of claim 1 , wherein specific productivity of the cell culture has increased by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or 75%.

16. The method of claim 1 , wherein the cell culture has a relative viable cell density of between about 1% and about 30% compared to a control cell culture that does not have reduced miRNA-let-7a activity.

17. A cell culture medium for producing a recombinant polypeptide in a mammalian cell comprising: a miRNA-let-7a microRNA inhibitor and a buffer, salt, carbohydrate, amino acid, vitamin, and trace essential element.

18. A recombinant polypeptide produced from a mammalian cell culture comprising mammalian cells transfected with an antisense microRNA inhibitor of miRNA-let-7a.

19. The cell culture medium of claim 17 , wherein the microRNA inhibitor is an antisense inhibitor of miRNA-let-7a.

20. A host cell having reduced miRNA-let-7a activity capable of producing a recombinant polypeptide comprising a vector encoding the recombinant polypeptide and wherein the miRNA-let-7a activity is reduced by a microRNA inhibitor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: STREICHER, KATIE; JACOBS, JONATHAN; GEORGANTAS III, ROBERT W.; GREENLEES, LYDIA; RANADE, KOUSTUBH
To: MEDIMMUNE, LLC
Reel/Frame 039564/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: BOWEN, MICHAEL A.
To: MEDIMMUNE, LLC
Reel/Frame 039564/0197 →
Continuity (2)
Provisional Application 61782180 · Mar 14, 2013
Related Publication 20160024502A1 · Jan 28, 2016